<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569010</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0291</org_study_id>
    <nct_id>NCT00569010</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Randomized Phase I/II Study of 5-Azacytidine in Combination With Cytosine Arabinoside in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome - &quot;SPORE&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of Azacytidine
      (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of patients with
      relapsed and/or refractory Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome
      (MDS). The safety and effectiveness of this treatment combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-azacytidine is designed to &quot;turn off&quot; the growth of cancer cells. This may be increased by
      ara-C, which is designed to kills leukemia cells by helping to stop the cells from dividing.

      If you are found to be eligible to take part in this study, you will be assigned to a
      treatment group. You will be randomly assigned (as in the toss of a coin) to one of the 4
      treatment groups. The first 3 to 6 patients will be assigned to Group 1. If no serious side
      effects are experienced, the next 3 to 6 patients will be assigned to Group 2. If no serious
      side effects are experienced, the next 3 to 6 patients will be assigned to Group 3. If no
      serious side effects are experienced, the next 3 to 6 patients will be assigned to Group 4.

      If you are in Group 1, you will receive low-dose 5-azacytidine as an infusion by vein over 20
      to 30 minutes every day for 7 days. You will also receive low-dose ara-C as a continuous
      infusion by vein for 7 days.

      If you are in Group 2, you will receive high-dose 5-azacytidine as an infusion by vein over
      20 to 30 minutes every day for 7 days. You will also receive low-dose ara-C as a continuous
      infusion by vein for 7 days.

      If you are in Group 3, you will receive low-dose 5-azacytidine as an infusion by vein over 20
      to 30 minutes every day for 7 days. You will also receive high-dose ara-C as a continuous
      infusion by vein for 3 days (if you are 65 years of age or older) or for 4 days (if you are
      younger than 65 years of age).

      If you are in Group 4, you will receive high-dose 5-azacytidine as an infusion by vein over
      20 to 30 minutes every day for 7 days. You will also receive high-dose ara-C as a continuous
      infusion by vein for 3 days (if you are 65 years of age or older) or for 4 days (if you are
      younger than 65 years of age).

      Each group's treatment will be repeated every 4 to 8 weeks (this is considered 1 cycle of
      treatment), depending on your blood counts and how well your bone marrow is recovering. You
      will receive at least 2 cycles of treatment. You will continue to receive treatment, unless
      your disease gets worse or if you experience intolerable side effects. If your disease gets
      worse or you experience intolerable side effects, you may be taken off this study.

      This is an investigational study. 5-azacytidine has been approved by the FDA for the
      treatment of MDS. Ara-C has been approved by the FDA for the treatment of AML. Up to 80
      patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Remission</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical response is determined by achievement of a complete remission (CR) as judged by morphological criteria (&lt; 1% blasts in bone marrow with neutrophil recovery) according to International Working Group (IWG) criteria.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Low-Dose Ara-C + AZA-Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 = Low-Dose Ara-C + Azacitidine-Level 0
Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Ara-C + AZA-Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 = Low-Dose Ara-C + Azacitidine-Level 1
Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Ara-C + AZA-Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Ara-C + AZA-Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 = High-Dose Ara-C + Azacitidine-Level 1
High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
    <arm_group_label>Low-Dose Ara-C + AZA-Level 0</arm_group_label>
    <arm_group_label>Low-Dose Ara-C + AZA-Level 1</arm_group_label>
    <arm_group_label>High-Dose Ara-C + AZA-Level 0</arm_group_label>
    <arm_group_label>High-Dose Ara-C + AZA-Level 1</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days
Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age&lt;65 years) or 3 days (age&gt;=65 years)</description>
    <arm_group_label>Low-Dose Ara-C + AZA-Level 0</arm_group_label>
    <arm_group_label>Low-Dose Ara-C + AZA-Level 1</arm_group_label>
    <arm_group_label>High-Dose Ara-C + AZA-Level 0</arm_group_label>
    <arm_group_label>High-Dose Ara-C + AZA-Level 1</arm_group_label>
    <other_name>Cytosar-U</other_name>
    <other_name>cytarabine</other_name>
    <other_name>cytosine Arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically confirmed Acute Myeloid Leukemia (AML) or high risk
             and previously treated Myelodysplastic Syndrome (MDS).

          2. Patients with (1) refractory disease or (2) first relapse within 6 months of therapy
             or (3) 2nd or more of relapse of Acute Myelogenous Leukemia (AML) or high risk
             Myelodysplastic Syndrome MDS will be considered for the study.

          3. Patients must have been off chemotherapy for 4 weeks prior to entering this study and
             recovered from the toxic effects of that therapy, unless there is evidence of rapidly
             progressive disease.

          4. Age &gt;=18 years. Deoxyribonucleic acid (DNA) methylation plays a significant role in
             development, and the effects of azacitidine in children are not well described.

          5. Patients must have normal organ as defined: Total bilirubin &lt;2 mg, aspartate
             aminotransferase (AST)/alanine aminotransferase (ALT) &lt;2.5 x institutional upper limit
             of normal, Creatinine &lt;2 mg

          6. Ability to understand and the willingness to sign a written informed consent document.

          7. Women of child bearing potential must have a negative serum pregnancy test prior to
             azacitidine treatment.

          8. Women of child bearing potential should be advised to avoid becoming pregnant and men
             should be advised to not father a child while receiving treatment with azacytidine.

          9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

        Exclusion Criteria:

          1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier,
             unless there is evidence of rapidly progressive disease. Patients may have received
             hydroxyurea prior to entering the study.

          2. Patients may not be receiving any other investigational agents for their leukemias.

          3. Patients with active brain or meningeal disease should be excluded.

          4. Known or suspected hypersensitivity to azacitidine or mannitol

          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          6. Pregnant women are excluded from this study because azacitidine is a Deoxyribonucleic
             acid (DNA) methyltransferase inhibitor which has teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with azacitidine, breastfeeding should be
             discontinued if the mother is treated with azacitidine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Issa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <results_first_submitted>January 21, 2011</results_first_submitted>
  <results_first_submitted_qc>January 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 14, 2011</results_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 12/28/2005 to 8/25/2008. All participants were registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 36 enrolled, only 34 evaluable participants were included in this study and started study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low-Dose Ara-C + AZA-Level 0</title>
          <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days; Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days</description>
        </group>
        <group group_id="P2">
          <title>Low-Dose Ara-C + AZA-Level 1</title>
          <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
        </group>
        <group group_id="P3">
          <title>High-Dose Ara-C + AZA-Level 0</title>
          <description>Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65years); AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days</description>
        </group>
        <group group_id="P4">
          <title>High-Dose Ara-C + AZA-Level 1</title>
          <description>High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65 years); AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-Dose Ara-C + AZA-Level 0</title>
          <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days; Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days</description>
        </group>
        <group group_id="B2">
          <title>Low-Dose Ara-C + AZA-Level 1</title>
          <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>High-Dose Ara-C + AZA-Level 0</title>
          <description>Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65years); AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days</description>
        </group>
        <group group_id="B4">
          <title>High-Dose Ara-C + AZA-Level 1</title>
          <description>High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65 years); AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="31" upper_limit="76"/>
                    <measurement group_id="B2" value="61" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="B3" value="74" lower_limit="52" upper_limit="79"/>
                    <measurement group_id="B4" value="62" lower_limit="38" upper_limit="69"/>
                    <measurement group_id="B5" value="61" lower_limit="31" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Remission</title>
        <description>Clinical response is determined by achievement of a complete remission (CR) as judged by morphological criteria (&lt; 1% blasts in bone marrow with neutrophil recovery) according to International Working Group (IWG) criteria.</description>
        <time_frame>6 weeks</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Dose Ara-C + AZA-Level 0</title>
            <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days; Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days</description>
          </group>
          <group group_id="O2">
            <title>Low-Dose Ara-C + AZA-Level 1</title>
            <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>High-Dose Ara-C + AZA-Level 0</title>
            <description>Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65years); AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days</description>
          </group>
          <group group_id="O4">
            <title>High-Dose Ara-C + AZA-Level 1</title>
            <description>High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65 years); AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Remission</title>
          <description>Clinical response is determined by achievement of a complete remission (CR) as judged by morphological criteria (&lt; 1% blasts in bone marrow with neutrophil recovery) according to International Working Group (IWG) criteria.</description>
          <population>Analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low-Dose Ara-C + AZA-Level 0</title>
          <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days; Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days</description>
        </group>
        <group group_id="E2">
          <title>Low-Dose Ara-C + AZA-Level 1</title>
          <description>Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
        </group>
        <group group_id="E3">
          <title>High-Dose Ara-C + AZA-Level 0</title>
          <description>Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65years); AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days</description>
        </group>
        <group group_id="E4">
          <title>High-Dose Ara-C + AZA-Level 1</title>
          <description>High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age&lt;65years) or 3 days (age&gt;=65 years); AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Disease</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Occular/Visual other 20/400</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colotis</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean-Pierre Issa, M.D./Professor</name_or_title>
      <organization>The University of MD Anderson Cancer Center</organization>
      <phone>713-745-2260</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

